| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11912-004-0062-X |
| P698 | PubMed publication ID | 15291979 |
| P50 | author | Barbara Pro | Q41599457 |
| P2093 | author name string | Anas Younes | |
| Barbara Pro | |||
| P2860 | cites work | Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells | Q24679724 |
| Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma | Q27851513 | ||
| The biology of VEGF and its receptors | Q27860704 | ||
| CD40-CD40 ligand | Q28143324 | ||
| Potential for proteasome inhibition in the treatment of cancer | Q28186033 | ||
| The TNF and TNF receptor superfamilies: integrating mammalian biology | Q28203717 | ||
| Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival | Q28205125 | ||
| Signalling pathways of the TNF superfamily: a double-edged sword | Q29616428 | ||
| Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma | Q33332247 | ||
| To die or not to die--the quest of the TRAIL receptors | Q33637080 | ||
| The dynamics of life and death of malignant lymphocytes | Q33743396 | ||
| CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders | Q33777531 | ||
| The soluble CD40 ligand sCD154 in systemic lupus erythematosus | Q33858548 | ||
| Targeting mTOR signaling for cancer therapy | Q34220084 | ||
| CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies | Q34266298 | ||
| Receptor-mediated choreography of life and death. | Q34274842 | ||
| Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. | Q34469691 | ||
| Targeting death and decoy receptors of the tumour-necrosis factor superfamily | Q34791120 | ||
| Focus on lymphomas | Q35008948 | ||
| How the ubiquitin-proteasome system controls transcription | Q35075758 | ||
| Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice | Q35110335 | ||
| Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders | Q35184335 | ||
| Survival and proliferation factors of normal and malignant plasma cells | Q35211028 | ||
| Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy | Q35218070 | ||
| Will mTOR inhibitors make it as cancer drugs? | Q35604822 | ||
| Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. | Q35610634 | ||
| Targeting PI3K-AKT pathway for cancer therapy | Q35648847 | ||
| Mammalian target of rapamycin inhibition as therapy for hematologic malignancies | Q35653049 | ||
| PI3K/Akt signalling pathway and cancer. | Q35692250 | ||
| Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations | Q36375661 | ||
| BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone | Q36663554 | ||
| Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors | Q40526021 | ||
| Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors | Q40558321 | ||
| Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. | Q40772885 | ||
| Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies | Q40963683 | ||
| Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines | Q41378283 | ||
| CD40 antigen expression on Reed-Sternberg cells. A reliable diagnostic tool for Hodgkin's disease | Q42790570 | ||
| Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II. | Q43269283 | ||
| Thalidomide for patients with recurrent lymphoma | Q44800302 | ||
| Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines | Q46218487 | ||
| Analysis of the PI-3-Kinase-PTEN-AKT pathway in human lymphoma and leukemia using a cell line microarray. | Q47830079 | ||
| Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. | Q53330746 | ||
| Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA) | Q57219095 | ||
| From angiogenesis to lymphangiogenesis | Q60488492 | ||
| BCL-2 antisense therapy in patients with non-Hodgkin lymphoma | Q61868294 | ||
| Angiogenesis induced by B-cell non-Hodgkin's lymphomas. Lack of correlation with tumor malignancy and immunologic phenotype | Q67660312 | ||
| Diagnostic significance of CD40, CD40L, and CD26 expression in Hodgkin's disease and other lymphomas | Q71009095 | ||
| Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells | Q71918643 | ||
| Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas | Q73340882 | ||
| Promise and problems of Bcl-2 antisense therapy | Q73529352 | ||
| Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia | Q74122283 | ||
| Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis | Q77768132 | ||
| Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival | Q78290422 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 360-368 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Current Oncology Reports | Q2264969 |
| P1476 | title | New molecular targets for treatment of lymphoma | |
| P478 | volume | 6 |
| Q36429727 | Novel treatment strategies for aggressive non-Hodgkin's lymphoma | cites work | P2860 |
Search more.